Form 4: Ankit Mahadevia Sells Spero Therapeutics Stock to Cover Tax Obligations

Director Ankit Mahadevia sold shares of Spero Therapeutics common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• Ankit Mahadevia, a director of Spero Therapeutics, sold shares of the company's common stock on February 5, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on February 1, 2022, and February 1, 2023.
• A total of 13,959 shares were sold at a price of $0.78 per share to cover RSUs granted in 2022.
• An additional 55,260 shares were sold at $0.78 per share to cover RSUs granted in 2023.
• Following these transactions, Mahadevia directly owns 689,866 shares of Spero Therapeutics common stock.
• Mahadevia also indirectly owns 65,817 shares through the Mahadevia-Mehta Family Trust, where he serves as a trustee.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects a routine transaction to cover tax obligations related to vested RSUs. It doesn't indicate a change in the director's overall confidence in the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among company executives and directors. This transaction reflects a standard procedure for managing personal tax liabilities associated with equity compensation.

Stakeholder Impact

• The sale of shares by a director could have a minor, temporary impact on the stock price due to increased selling pressure.
• However, since the sale is for tax obligations, it's unlikely to significantly alter investor sentiment.

Key Dates

Keywords

Spero Therapeutics, Ankit Mahadevia, stock sale, Form 4, RSUs, tax withholding, director, SPRO